Skip to content
AI IntelligenceJul 13, 2026Secondary Market
Article

ESALY

The FDA approved LEQEMBI IQLIK (lecanemab-irmb) subcutaneous injection as an initiation dose for early Alzheimer's disease. The approval marks the first-of-its-kind anti-amyloid treatment worldwide, allowing at-home dosing.

Data Cube AI EditorialSource: PR Newswire
01

Source Brief

The FDA approved LEQEMBI IQLIK (lecanemab-irmb) subcutaneous injection as an initiation dose for early Alzheimer's disease. The approval marks the first-of-its-kind anti-amyloid treatment worldwide, allowing at-home dosing.